H.C. Wainwright raises Ligand Pharma price target on royalty growth By Investing.com

H.C. Wainwright raised Ligand Pharma’s price target to $243 from $239 and kept a Buy rating after the FDA fully approved FILSPARI for focal segmental glomerulosclerosis, expanding the drug into a second rare kidney disease. The approval broadens Ligand’s royalty stream, with the firm estimating $40 million to $45 million in royalty revenue by 2030 and total U.S. addressable patients above 100,000. Ligand also reported Q4 revenue of $59.7 million versus $55.6 million expected and adjusted EPS of $2.02 versus $1.50 consensus.

Analysis

LGND is not just a royalty story; this is a duration asset re-rating as the market starts capitalizing a second indication with a much larger addressable base. The first-order move is obvious, but the second-order effect is more important: every new label expansion lowers perceived binary risk around the asset and increases the probability that Ligand’s royalty stream gets treated like an annuity rather than a biotech cash flow, which can compress the discount rate applied to the entire platform.

The cleaner read-through is to TVTX, but the market may be underestimating how much of this is already reflected after a strong run. The real catalyst path is not just launch uptake; it is payer friction, nephrologist adoption, and whether the FSGS label broadens prescribing enough to create a visible quarterly acceleration over the next 2-4 quarters. If early scripts disappoint, the stock can retrace quickly because the current setup leaves little margin for error near highs.

The contrarian angle is that the approval may be a bigger multiple event for LGND than a near-term earnings event. A fixed 9% royalty on an expanding indication is attractive, but the equity’s sensitivity now depends on how capital allocators judge persistence versus growth: if FILSPARI becomes a two- or three-indication asset with durable uptake, upside extends; if not, the move looks like a front-loaded rerating on peak enthusiasm. OPY is essentially noise here and should not distract from the primary economics.

Key Decisions for Investors

• Long LGND on modest pullbacks over the next 1-2 weeks; target a 10-15% upside re-rating if the market starts capitalizing the expanded royalty stream, with downside limited by the now-lower approval overhang.
• Trade TVTX tactically around launch data: buy on post-event weakness only if script/channel checks confirm early adoption; otherwise fade strength near highs, since the stock likely needs at least 1-2 clean quarters to justify further multiple expansion.
• Pair trade: long LGND / short a basket of slower-growing royalty names with less visibility into 2025-2026 cash flows; the thesis is that LGND deserves a premium for repeated label expansion optionality and cleaner monetization.
• For event-driven accounts, consider LGND call spreads 3-6 months out to capture continued rerating while limiting theta decay; best risk/reward if implied volatility remains elevated but not extreme.
• Do not chase the move after a single approval headline; wait for either first prescription data or management commentary on royalty trajectory, because the second-order question is adoption speed, not regulatory success.